Circulating Tumor Cell Market Size, Share, Growth Analysis, By Product(Kits & Reagents, Blood Collection Tubes, Devices or Systems), By Specimen(Blood, Bone Marrow, other body fluid), By Technology(CTC Detection (Immunocapture, Size-based separation, Density Based Separation, Combined Methods)), By Application(Clinical Liquid Biopsy (Risk Assessment, Screening and Monitoring), Research (Cancer Stem Cell, Drug Therapy Development)), By End User(Hospitals & Clinics, Research & Academic Institutes, Diagnostic Centers), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35H2232 | Region: Global | Published Date: June, 2024
Pages: 219 |Tables: 150 |Figures: 78

Circulating Tumor Cell Market Insights

Circulating Tumor Cell Market size was valued at USD 11.38 Billion in 2023 and is poised to grow from USD 12.55 Billion in 2024 to USD 27.51 Billion by 2032, growing at a CAGR of 10.3% during the forecast period (2025-2032).

The global Circulating Tumor Cell (CTC) market provides promising marketplace dynamics formed by means of advancements in most cancers diagnostics. The growing occurrence of most cancers fuels demand for non-invasive diagnostic gear like CTC evaluation. Key drivers include the growing emphasis on personalised medicinal drug and the need for early most cancers detection. However, challenges such as technological complexity and the want for standardization avert massive adoption. ELISA and PCR-based totally strategies dominate product sorts. North America holds a tremendous market share due to well-established healthcare infrastructure. The market is characterized through ongoing research, collaborations, and product innovations to address evolving medical wishes.

Market snapshot - 2025-2032

Global Market Size

USD 10.32 Billion

Largest Segment

Clinical Liquid Biopsy

Fastest Growth

Clinical Liquid Biopsy

Growth Rate

10.3% CAGR

Circulating Tumor Cell Market ($ Bn)
Country Share for North America Region (%)

To get more reports on the above market click here to Buy The Report

Circulating Tumor Cell Market Segmental Analysis

The global circulating tumor cell market is segmented into product, specimen, technology, application, end user, and region. Based on product, the market is segmented into Kits & Reagents, Blood Collection Tubes, Devices or Systems. Based on specimen, the market is segmented into Blood, Bone Marrow, other body fluid. Based on technology, the market is segmented into CTC Detection (Immunocapture, Size-based separation, Density Based Separation, Combined Methods), CTC Detection method (SERS, Microscopy, Others), CTC Analysis. Based on application, the market is segmented into Clinical Liquid Biopsy (Risk Assessment, Screening and Monitoring), Research (Cancer Stem Cell, Drug Therapy Development). Based on end user, the market is segmented into Hospitals & Clinics, Research & Academic Institutes, Diagnostic Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Analysis by Technology Type

CTC Enrichment is expected to dominate the market. Enrichment strategies, which includes nice and bad choice, filtration, and immunocapture, are pivotal in setting apart CTCs from blood samples. The versatility and efficiency of enrichment technologies in capturing uncommon circulating tumor cells make contributions to their substantial adoption, making them the dominant generation in the Circulating Tumor Cell marketplace.

Microchips are expected to be the quickest-growing era within the Circulating Tumor Cell marketplace. Microchip-based totally CTC detection leverages microfluidic structures to isolate and examine CTCs efficiently. The increasing demand for high-throughput, specific, and label-loose CTC evaluation drives the boom of the microchip era. Its potential to provide real-time records and enable single-mobile evaluation positions microchips as a rapidly evolving and modern era inside the CTC market.

Analysis by Application

The Cancer Detection utility phase is anticipated to dominate the Circulating Tumor Cell (CTC) market. Early cancer detection is a vital element in improving patient consequences, and CTC evaluation performs a critical position in figuring out and tracking cancer at an early stage. The Cancer Detection phase, encompassing numerous cancer kinds, is possibly to have significant adoption due to the growing emphasis on timely analysis for powerful treatment techniques.

The Monitoring and Prognosis utility segment is anticipated to be the fastest-growing. Continuous monitoring of CTCs gives valuable records for sickness progression and treatment reaction. As personalised medicinal drug gains prominence, the Monitoring and Prognosis segment is predicted to witness fast growth. It lets in clinicians to tailor treatment options primarily based on real-time facts, contributing to extra powerful and customized cancer control.

Circulating Tumor Cell Market By Application

To get detailed analysis on other segments, Request For Free Sample Report

Circulating Tumor Cell Market Regional Insights

North America is poised to dominate the Circulating Tumor Cell (CTC) market. This dominance can be attributed to the location's advanced healthcare infrastructure, widespread research and development activities, and excessive prevalence of most cancer cases. Robust assist from healthcare establishments and a nicely-hooked up regulatory framework contribute to the sizeable adoption of CTC technologies, positioning North America as a leader in the market.

Asia-Pacific is expected to be the quickest-developing place in the CTC marketplace. Factors which include the growing occurrence of most cancers, growing consciousness of the approximately advanced diagnostic era, and huge healthcare investments make contributions to the area's increase. Additionally, efforts to enhance healthcare accessibility and affordability in nations like China and India are anticipated to pressure the adoption of CTC era for most cancers analysis and tracking, making Asia-Pacific a key player within the market's fast growth.

Circulating Tumor Cell Market By Region
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Circulating Tumor Cell Market Dynamics

Drivers

Increasing Incidence Of Cancer Worldwide

  • The growing occurrence of cancer internationally has heightened the call for superior diagnostic equipment, with CTC evaluation emerging as a non-invasive and precious method for cancer detection and tracking. The emphasis on customized medicine and the want for early most cancers diagnosis similarly as the adoption of CTC technologies.

Restraints

High Technological Complexity And The Need For Standardization

  • One of the main market restraints is the technological complexity and the want for standardization in CTC analysis techniques pose demanding situations, affecting substantial adoption. Additionally, issues associated with the reliability and reproducibility of CTC effects preclude their incorporation into habitual medical practice.

Request Free Customization of this report to help us to meet your business objectives.

Circulating Tumor Cell Market Competitive Landscape

The competitive environment of the Circulating Tumor Cell market is dynamic and characterised by using the presence of key industry players actively shaping the market dynamics. Companies play pivotal roles, conducting strategic tasks to maintain and decorate their market positions. Ongoing studies and development activities focused on technological advancements and the creation of innovative CTC analysis answers are well-known.

Top Player’s Company Profiles

  • Janssen Diagnostics (Johnson & Johnson)
  • Sysmex America, Inc.
  • Qiagen
  • Roche Diagnostics
  • BD (Becton, Dickinson and Company)
  • Macrogenics, Inc.
  • Personalis, Inc.
  • ANGLE PLC
  • ApoCell, Inc.
  • RareCyte, Inc.
  • Exosomedx
  • Grail, Inc.
  • Invivoscribe Technologies, LLC
  • Epic Sciences, Inc.
  • Circulating Biomarkers LLC
  • ClariCell, Inc.
  • Thrive Earlier Detection
  • Ellumen
  • Hera BioLabs
  • CellMax Life Technologies

Recent Developments

  • In March 2024, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration.  

  • In January 2024, Veracyte announced that it has reached a definitive agreement to acquire C2i Genomics, expanding its diagnostics platform to include whole-genome minimal residual disease (MRD) detection capabilities from cell-free DNA (cfDNA) in liquid biopsies. The MRD testing that C2i offers uses artificial intelligence (AI) to create circulating tumor DNA signatures by comparing the genomics of the patient’s tumor and blood, disposing of the need for bespoke biomarker panels. 

  • In January 2024, Allogene Therapeutics Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products, and Foresight Diagnostics, the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection announced a strategic partnership to develop a minimal residual disease (MRD) in-vitro diagnostic (IVD) to determine eligibility in ALPHA3, the first pivotal trial for first line (1L) consolidation treatment of large B-cell lymphoma (LBCL).

Circulating Tumor Cell Key Market Trends

  • Rising Shift Towards The Integration Of Ctc Analysis Into Routine Clinical Practice: The discernible shift toward the combination of CTC evaluation into ordinary medical exercise, pushed with the aid of its potential for real-time tracking of cancer progression and remedy reaction. The ongoing improvement of progressive technologies, which includes microfluidic systems and superior molecular detection methods, displays a fashion closer to higher precision and sensitivity in CTC analysis. Moreover, the growing cognizance of liquid biopsy methods in cancer diagnostics amplifies the significance of CTCs as valuable biomarkers.

Circulating Tumor Cell Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

Global Circulating Tumor Cell marketplace evaluation exhibits a dynamic marketplace with a number of standout traits and problems. The marketplace is driven by using the rising international cancer prevalence, increasing demand for non-invasive diagnostic equipment, and improvements in CTC enrichment and detection technology. However, challenges include the complexity of CTC evaluation and the want for standardization. Enrichment technologies dominate the product panorama, with North America main regionally because of advanced healthcare infrastructure. Key traits include the mixing of CTC evaluation into recurring scientific practice and ongoing research in microfluidic structures. Collaborations and innovations underline the aggressive panorama, reflecting a trend closer to precision diagnostics in most cancers.

Report Metric Details
Market size value in 2023 USD 11.38 Billion
Market size value in 2032 USD 27.51 Billion
Growth Rate 10.3%
Base year 2024
Forecast period 2025-2032
Forecast Unit (Value) USD Billion
Segments covered
  • Product
    • Kits & Reagents, Blood Collection Tubes, Devices or Systems
  • Specimen
    • Blood, Bone Marrow, other body fluid
  • Technology
    • CTC Detection (Immunocapture, Size-based separation, Density Based Separation, Combined Methods), CTC Detection method (SERS, Microscopy, Others), CTC Analysis
  • Application
    • Clinical Liquid Biopsy (Risk Assessment, Screening and Monitoring), Research (Cancer Stem Cell, Drug Therapy Development)
  • End User
    • Hospitals & Clinics, Research & Academic Institutes, Diagnostic Centers
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Janssen Diagnostics (Johnson & Johnson)
  • Sysmex America, Inc.
  • Qiagen
  • Roche Diagnostics
  • BD (Becton, Dickinson and Company)
  • Macrogenics, Inc.
  • Personalis, Inc.
  • ANGLE PLC
  • ApoCell, Inc.
  • RareCyte, Inc.
  • Exosomedx
  • Grail, Inc.
  • Invivoscribe Technologies, LLC
  • Epic Sciences, Inc.
  • Circulating Biomarkers LLC
  • ClariCell, Inc.
  • Thrive Earlier Detection
  • Ellumen
  • Hera BioLabs
  • CellMax Life Technologies
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Circulating Tumor Cell Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Circulating Tumor Cell Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Circulating Tumor Cell Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Circulating Tumor Cell Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Circulating Tumor Cell Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Circulating Tumor Cell Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Circulating Tumor Cell Market size was valued at USD 11.38 Billion in 2023 and is poised to grow from USD 12.55 Billion in 2024 to USD 27.51 Billion by 2032, growing at a CAGR of 10.3% during the forecast period (2025-2032).

The competitive environment of the Circulating Tumor Cell market is dynamic and characterised by using the presence of key industry players actively shaping the market dynamics. Companies play pivotal roles, conducting strategic tasks to maintain and decorate their market positions. Ongoing studies and development activities focused on technological advancements and the creation of innovative CTC analysis answers are well-known. 'Janssen Diagnostics (Johnson & Johnson)', 'Sysmex America, Inc.', 'Qiagen', 'Roche Diagnostics', 'BD (Becton, Dickinson and Company)', 'Macrogenics, Inc.', 'Personalis, Inc.', 'ANGLE PLC', 'ApoCell, Inc.', 'RareCyte, Inc.', 'Exosomedx', 'Grail, Inc.', 'Invivoscribe Technologies, LLC', 'Epic Sciences, Inc.', 'Circulating Biomarkers LLC', 'ClariCell, Inc.', 'Thrive Earlier Detection', 'Ellumen', 'Hera BioLabs', 'CellMax Life Technologies'

The growing occurrence of cancer internationally has heightened the call for superior diagnostic equipment, with CTC evaluation emerging as a non-invasive and precious method for cancer detection and tracking. The emphasis on customized medicine and the want for early most cancers diagnosis similarly as the adoption of CTC technologies.

Rising Shift Towards The Integration Of Ctc Analysis Into Routine Clinical Practice: The discernible shift toward the combination of CTC evaluation into ordinary medical exercise, pushed with the aid of its potential for real-time tracking of cancer progression and remedy reaction. The ongoing improvement of progressive technologies, which includes microfluidic systems and superior molecular detection methods, displays a fashion closer to higher precision and sensitivity in CTC analysis. Moreover, the growing cognizance of liquid biopsy methods in cancer diagnostics amplifies the significance of CTCs as valuable biomarkers.

North America is poised to dominate the Circulating Tumor Cell (CTC) market. This dominance can be attributed to the location's advanced healthcare infrastructure, widespread research and development activities, and excessive prevalence of most cancer cases. Robust assist from healthcare establishments and a nicely-hooked up regulatory framework contribute to the sizeable adoption of CTC technologies, positioning North America as a leader in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Circulating Tumor Cell Market

Report ID: SQMIG35H2232

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE